New Alzheimer's drug shows promise in early trial

NCT ID NCT05811442

Completed Disease control Sponsor: Beijing Joekai Biotechnology LLC Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested a new drug called 50561 in 68 people with mild to moderate Alzheimer's disease. Participants received either a high dose, low dose, or a placebo. The main goal was to see if the drug could slow down cognitive decline over 24 weeks using a standard memory and thinking test.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 50561
What this could lead to: If successful, this could point toward a new treatment to slow cognitive decline in Alzheimer's disease.
What could go wrong: This is an early Phase IIa trial with only 68 participants, so results may not be conclusive. The drug may not show meaningful benefit over placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER'S DISEASE

Contacts and locations

Locations

Beijing Anding Hospital, Capital Medical University

Beijing, Beijing Municipality, China
Beijing Friendship Hospital, Capital Medical University

Beijing, Beijing Municipality, China
Beijing Tiantan Hospital, Capital Medical University

Beijing, Beijing Municipality, China
Heilongjiang Provincial Hospital of Traditional Chinese Medicine

Haerbin, Heilongjiang, China
Sir Run Run Shaw Hospital

Hangzhou, Zhejiang, China
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University

Guangzhou, Guangdong, China
The First Bethune Hospital of Jilin University

Changchun, Jilin, China
The First affiliated hospital of SOOCHOW university

Suzhou, Jiangsu, China
The Second Affiliated Hospital of Nanjing Medical University

Nanjing, Jiangsu, China
Tianjin Huanhu Hospital

Tianjin, Tianjin Municipality, China
Wuhan Union Hospital of China

Wuhan, Hubei, China
Xuanwu Hospital, Capital Medical University

Beijing, Beijing Municipality, 100053, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.